The transdermal fluid removal spinout will aim for a close of at least $426,000 with another $99,400 from private investors.

Renephra, a UK-based transdermal fluid removal spinout of University of Manchester and Manchester University NHS Foundation Trust, has received £231,000 ($327,000) from investors including regional public-private partnership GM&C Life Sciences Fund.

Investment management firm Deepbridge Capital also took part in the round, which is expected to close with $426,000 with the inclusion of at least $99,000 in additional funding from private investors.

GM&C Life Sciences is managed by venture capital and private equity firm Catapult Ventures. 

Renephra is working on…